EGFR-TKIs
10 abstracts
Abstract
EGFR-TKI as neoadjuvant treatment in patients with NSCLC with EGFR sensitive mutation: A retrospective real-world analysis.Org: First Affiliated Hospital of Guangzhou Medical University,
Abstract
IGF-1R, E-cadherin, N-cadherin, and occludin gene expression and resistance to EGFR tyrosine-kinase inhibitors in patients with lung adenocarcinoma in Serbia.Org: Montefiore New Rochelle, Institute for Oncology and Radiology of Serbia, University of Belgrade, Department of Pharmacology and Toxicology, University of Novi Sad, Institute for Pulmonary Diseases of Vojvodina,
Abstract
Immune infiltrate characterization and differential gene expression by RNA-sequencing analysis in patients with oncogene-addicted NSCLC with early progression under targeted therapy.Org: Genomic Platform and Biobank, AMMICa UAR3655/US23, Gustave Roussy, Cancer Campus,
Abstract
Real-world clinical outcomes in Chinese patients with EGFR-mutated NSCLC progressed from first-line EGFR-TKI: A prospective multicenter study.Org: Department of Pulmonary and Critical Care Medicine, Precision Medicine Key Laboratory of Sichuan Province, Suzhou Municipal Hospital, Shenyang Chest Hospital, Medicine and Frontier Science Center of Disease Molecular Network,
Abstract
CfDNA NGS detection of fusions acquired as mechanisms of resistance in the post-EGFR setting across multiple solid tumors.Org: Guardant Health Inc., Palo Alto University, CanSino Biologics, Guardant Health, Inc., Redwood City, CA,
Abstract
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).Org: National Cancer Center Hospital East, Kashiwa, Japan, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Osaka International Cancer Institute, Osaka, Japan, Kanagawa Cancer Center, Itami City Hospital,
Abstract
Correlation analysis of MRD positivity after non-small cell lung cancer surgery.Org: Guiqian International Hospital, GeneCast Biotechnology, Chengdu Origen Biotechnology,
Abstract
Gut microbiota profiling and clinical response in patients with metastatic non-small cell lung cancer receiving endothelial growth factor-tyrosine kinase inhibitors (EGFR-TKI).Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital,
Abstract
Transcriptomic subtype, TP53 mutation status, and APOBEC mutation signature in early-stage EGFR-mutant non-small-cell lung cancer.Org: Samsung Medical Center, Samsung Genome Institute, Samsung Medical Center, Seoul, South Korea, Samsung Medical Hospital, Sungkyunkwan University School of Medicine,
Abstract
Therapeutic effects of combination with EGFR-TKIs and radiotherapy on the prognosis of stage IV lung adenocarcinomas harboring 19-Del or 21-L858R: A retrospective study.Org: Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Jinan, China, Department of oncology, Shengli Oilfield Central Hospital,